| pubmed-article:17410097 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17410097 | lifeskim:mentions | umls-concept:C0021080 | lld:lifeskim |
| pubmed-article:17410097 | lifeskim:mentions | umls-concept:C0080202 | lld:lifeskim |
| pubmed-article:17410097 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17410097 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:17410097 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17410097 | pubmed:dateCreated | 2007-6-28 | lld:pubmed |
| pubmed-article:17410097 | pubmed:abstractText | While sirolimus (SRL) is thought to be a non-nephrotoxic agent, cyclosporine A (CsA) toxicity is a serious problem in kidney transplantation. We compared the effects of the two drugs on T-helper (Th) subsets in kidney transplant patients. We examined 24 first cadaver kidney recipients equally randomized to receive SRL/mycophenolate mofetil (MMF)/methylprednisolone (MP), or cyclosporine with either MMF or MP. The Th1 and Th2 subsets in peripheral blood were separated based on their production of interferon-gamma (INFgamma) or interleukin (IL)-4/IL-5. The lymphocytes were stimulated with phytohemoagglutinin or with allogenic CD3-depeted and irradiated antigen-presenting cells. Furthermore, the conversion potential of Th0 to Th1 was determined by measuring IL-12 and IL-18 levels after lipopolysaccharide challenge. When peripheral blood lymphocytes taken from SRL-treated patients were stimulated by phytohemoagglutinin, there were significantly lower INFgamma-producing cells compared with the lymphocytes taken from patients treated with CsA. The number of IL-4/IL-5-producing cells did not differ among the patient groups. Release of IL-12 but not IL-18 from peripheral lymphocytes following treatment with lipopolysaccharide was significantly lower in the SRL-treated patients. These results show that compared with CsA, SRL caused a significant decrease in the Th1 lymphocyte subset associated with a significant reduction of IL-12 release. | lld:pubmed |
| pubmed-article:17410097 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17410097 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17410097 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17410097 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:17410097 | pubmed:issn | 0085-2538 | lld:pubmed |
| pubmed-article:17410097 | pubmed:author | pubmed-author:SepeVV | lld:pubmed |
| pubmed-article:17410097 | pubmed:author | pubmed-author:Dal CantonAA | lld:pubmed |
| pubmed-article:17410097 | pubmed:author | pubmed-author:RampinoTT | lld:pubmed |
| pubmed-article:17410097 | pubmed:author | pubmed-author:LibettaCC | lld:pubmed |
| pubmed-article:17410097 | pubmed:author | pubmed-author:MeloniFF | lld:pubmed |
| pubmed-article:17410097 | pubmed:author | pubmed-author:ZucchiMM | lld:pubmed |
| pubmed-article:17410097 | pubmed:author | pubmed-author:PortalupiVV | lld:pubmed |
| pubmed-article:17410097 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17410097 | pubmed:volume | 72 | lld:pubmed |
| pubmed-article:17410097 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17410097 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17410097 | pubmed:pagination | 114-20 | lld:pubmed |
| pubmed-article:17410097 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:meshHeading | pubmed-meshheading:17410097... | lld:pubmed |
| pubmed-article:17410097 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17410097 | pubmed:articleTitle | The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. | lld:pubmed |
| pubmed-article:17410097 | pubmed:affiliation | Unit of Nephrology, Fondazione IRCCS Policlinico San Matteo, and University of Pavia, Italy. carmelo.libetta@unipv.it | lld:pubmed |
| pubmed-article:17410097 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17410097 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17410097 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17410097 | lld:pubmed |
